| Name | Title | Contact Details |
|---|
Why American Addiction Centers? We take a big picture approach to addiction recovery treatment – addressing the individual`s whole lifestyle in relation to substance use, alcohol and binge eating addiction and partnering with the family throughout the treatment process whenever possible. With our research-based programs, our inpatient treatment centers don`t just focus on the problem; we strengthen the individual and focus on the future. Whether it`s the initial clinical assessments, medically supervised detox, residential rehabilitation or aftercare, our team is present for and committed to each step of the recovery process for every individual. American Addiction Centers is an equal opportunity and drug free employer. All decisions regarding recruiting and hiring will be made without unlawful discrimination on the basis of race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, or age.
Omrix Biopharmeceuticals, Inc is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
THC.com is the safe place to connect about all things cannabis. THC.com is social media that supports YOU. Get paid on product endoresments!
Grace Management, Inc. is a nationally recognized leader in delivering senior living management service. Grace Management was established in 1984 and has built a reputation not only as a business leader in the senior living industry, but also as having developed a family-driven approach. Grace Management communities include independent living, cottage and estate homes, assisted living, and memory care that offer a diverse array of services and amenities catered to the individual.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.